The prognostic and therapeutic implications of TP53 expression in CMML

Daniel Wiseman, MBBS, PhD, University of Manchester, Manchester, UK, provides insight into the prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia (CMML). Dr Wiseman notes that agents acting as a p53 activator have shown synergy with azacitidine in CMML samples, suggesting a potential therapeutic approach for CMML patients with low TP53 expression. This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.